Phantom Neuro's Leap: Human Trials for Intuitive Prosthetics Begin

AUSTIN, Texas – April 15, 2026 – Neurotechnology firm Phantom Neuro has received approval to begin its first-in-human clinical study in Australia, a critical milestone for its innovative Phantom X system. The trial, named CYBORG, will test a minimally invasive muscle-machine interface designed to grant individuals with limb loss intuitive, near-natural control over prosthetic devices. This move from preclinical work to human implantation marks a significant step toward commercialization and a potential paradigm shift in the field of advanced prosthetics.

The Early Feasibility Study (EFS) signals a new chapter for the Austin-based company, which aims to bridge the gap between human intention and robotic action without the need for highly invasive surgery. The results could pave the way for U.S. clinical trials and, ultimately, bring a new class of high-functioning, user-friendly prosthetics to a wider audience.

The Phantom X: A New Paradigm in Control

At the heart of the trial is the Phantom X Control System, a technology that seeks to redefine the relationship between an amputee and their prosthetic. Unlike many neural interface technologies that require complex and high-risk procedures like direct brain or nerve surgery, Phantom Neuro’s approach is fundamentally different. It employs a small, implantable sensor array that is placed just under the skin of the residual limb during a simple outpatient procedure.

This array works by listening to the body’s own signals. It captures the subtle neuromuscular electrical activity generated when a person thinks about moving their missing limb. Sophisticated, proprietary software then decodes these muscle signals in real-time, translating them into precise commands that control a connected prosthetic hand or robotic device. The company claims that with just 10 minutes of calibration, the system can restore up to 85% of hand and wrist functionality, a remarkable feat.

The system’s minimally invasive nature stands in stark contrast to existing and emerging alternatives. While Brain-Computer Interfaces (BCIs) offer the tantalizing prospect of direct thought control, they often require implanting electrodes into the brain, carrying significant surgical risks. Other advanced techniques like Targeted Muscle Reinnervation (TMR) involve complex surgery to reroute nerves to different muscles, with rehabilitation often beginning 6-8 months post-op. Osseointegration, which anchors a prosthesis directly to the bone, provides stability but requires an extensive rehabilitation period and carries a persistent risk of infection at the implant site. Phantom Neuro aims to offer a compelling alternative that balances high performance with a significantly lower surgical burden.

The CYBORG Study: A Crucial First Step

The CYBORG study is designed to rigorously evaluate the safety and functional capabilities of the Phantom X system. The trial will enroll up to 10 participants with below-the-elbow, unilateral limb loss. The entire process will be conducted in Melbourne, Australia, leveraging the city's robust medical research infrastructure.

Surgical procedures will take place at Cabrini Health, a leading private hospital, under the guidance of Primary Investigator Dr. Michael Lo, a prominent plastic and reconstructive surgeon. Following the same-day implantation, participants will have a brief two-week recovery period before being fitted with a Phantom X-compatible prosthetic. Prosthetic care and the crucial rehabilitation phase will be managed by specialists at ProMotion Prosthetics and Enable Rehab.

"This approval represents a defining milestone for Phantom Neuro," said Connor Glass, the company's Founder and CEO, in a statement. "For the first time, we're moving from preclinical validation to human implantation. This study is designed to evaluate the safety of our system and begin validating that functional, real-time control of prosthetic devices can be achieved through a minimally invasive muscle interface."

Over an approximately 20-week period, each participant’s progress will be closely monitored, providing the company with invaluable data on the system's performance, durability, and user experience in a real-world setting.

Australia's Clinical Edge and the Path to Market

The decision by a U.S.-based company to conduct its first human trials in Australia is a strategic one. The country has cultivated a reputation for its efficient and clear regulatory pathways for early-stage clinical trials, making it an attractive destination for MedTech innovators looking to accelerate development timelines.

"We chose Australia for its efficient early-stage clinical trial pathways, and the results will support our U.S. FDA IDE and a future pivotal trial," explained Vinod Sharma, Phantom Neuro's Head of Clinical and Scientific Affairs. The data gathered from the CYBORG study will be foundational for the company’s submissions to the U.S. Food and Drug Administration (FDA).

Phantom Neuro has already received Breakthrough Device Designation and Targeted Acceleration Pathway (TAP) Designation from the FDA, programs designed to expedite the review and approval of novel medical devices that could provide more effective treatment for life-threatening or irreversibly debilitating conditions. The positive outcomes from the Australian trial will be instrumental in navigating this accelerated path in the United States.

A New Horizon for Amputees and Human-Machine Interaction

Beyond the technology and regulatory strategy lies the profound human impact. For individuals living with limb loss, current prosthetic options can often feel cumbersome, unintuitive, and frustrating to control. The learning curve is steep, and the devices can feel more like tools than extensions of the self. The promise of the Phantom X system is a more seamless and integrated experience, potentially reducing the cognitive load and psychological barriers associated with using a prosthesis.

By enabling control that mirrors natural movement, the technology could dramatically improve quality of life, restore a sense of agency, and allow users to perform daily tasks with greater ease and confidence. The company’s vision extends to a procedure that is accessible, capable of being performed by tens of thousands of surgeons, which could eventually democratize access to this level of advanced prosthetic control.

The project is backed by substantial scientific and financial credibility. Born from research at the prestigious Johns Hopkins University School of Medicine, Phantom Neuro has raised a total of $28 million. Its most recent $19 million Series A funding round was led by Ottobock, a global giant in the prosthetics industry. This strategic partnership, which includes a seat on Phantom Neuro's board, provides not just capital but deep market expertise. The company's advisory board further burnishes its credentials, featuring experts from DARPA, CTRL-Labs (acquired by Meta), and Synchron, underscoring the serious potential recognized by leaders across the neurotechnology landscape. As the CYBORG trial gets underway, it represents not just a test of a new device, but a tangible step toward a future where the boundary between human and machine becomes more intuitive than ever before.